FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2015477737> ?p ?o ?g. }

• W2015477737 abstract "To assess the clinical and cost-effectiveness of oxaliplatin in combination with 5-fluorouracil/leucovorin (5-FU/LV), and capecitabine monotherapy (within their licensed indications), as adjuvant therapies in the treatment of patients with Stage III (Dukes' C) colon cancer after complete surgical resection of the primary tumour, as compared with adjuvant chemotherapy with an established fluorouracil-containing regimen.Ten electronic bibliographic databases were searched from inception to January 2005. Searches were supplemented by hand searching relevant articles, sponsor and other submissions of evidence to the National Institute of Health and Clinical Excellence and conference proceedings.A systematic review and meta-analysis (where appropriate) of clinical efficacy evidence and a cost-effectiveness review and economic modelling were carried out. Marginal costs, life years gained and cost-effectiveness acceptability curves were estimated. Probabilistic sensitivity analysis was used to generate information on the likelihood that each of the interventions was optimal.Three randomised active-controlled trials, of varying methodological quality, were included in the review. The MOSAIC trial and NSABP C-07 study considered the addition of oxaliplatin to adjuvant treatment (albeit administered in different 5-FU/LV regimens) and the X-ACT study compared oral capecitabine with bolus 5-FU/LV alone. A review of the available evidence indicated that in patients with Stage III colon cancer, oxaliplatin in combination with an infusional de Gramont schedule of 5-FU/LV (FOLFOX4) was more effective in preventing and delaying disease recurrence than infusional 5-FU/LV alone (de Gramont regimen). Serious adverse events and treatment discontinuations due to toxicity were more evident with oxaliplatin-based regimens (FOLFOX4 and FLOX regimen) than infusional or bolus 5-FU/LV alone (de Gramont and Roswell Park regimen). Oral capecitabine was at least equivalent in disease-free survival to the bolus Mayo Clinic 5-FU/LV regimen for patients with resected Stage III colon cancer. Although, the safety and tolerability profile of capecitabine was superior to that of the Mayo Clinic 5-FU/LV regimen, it has not been evaluated in comparison with other less toxic 5-FU/LV regimens currently in common use in the UK. Based on the assumptions and survival analysis methods used, the cost-effectiveness analysis using economic modelling estimated that capecitabine was a dominating strategy and resulted in a cost-saving of approximately pound 3320 per patient in comparison with the Mayo Clinic 5-FU/LV regimen, while also providing an additional 0.98 quality-adjusted life-years (QALYs) over a 50-year model time horizon. Oxaliplatin in combination with 5-FU/LV (FOLFOX4 regimen) is estimated to cost an additional pound 2970 per QALY gained when compared with the de Gramont 5-FU/LV regimen and demonstrated superior survival outcomes with marginal costs. The uncertainty analysis suggests that both interventions have a high probability of being cost-effective at a threshold of both pound 20,000 and pound 30,000. An indirect comparison of the FOLFOX4 and Mayo Clinic 5-FU/LV regimens suggests that the use of FOLFOX4 in place of the Mayo Clinic 5-FU/LV regimen would cost an additional pound 5777 per QALY gained. An incremental cost-effectiveness ratio (ICER) is estimated to be approximately pound 13,000 per QALY gained from treatment with FOLFOX4 compared with capecitabine. However, if the Mayo Clinic and the de Gramont 5-FU/LV regimens are assumed to be equivalent in terms of effectiveness, the ICER of FOLFOX4 in comparison with capecitabine may be greater than pound 30,000 per QALY.The evidence suggests that both capecitabine and FOLFOX4 are clinically effective and cost-effective in comparison with 5-FU/LV regimens (Mayo Clinic and de Gramont schedules). Further research is suggested into the effectiveness, tolerability, patient acceptability and costs of different oxaliplatin/fluoropyrimidine schedules in the adjuvant setting; the effects of treatment duration on efficacy; adverse events; resource data collection strategies and reporting of summary statistics; subgroups benefiting most from adjuvant chemotherapy; and methods for estimating mean survival." @default.
• W2015477737 created "2016-06-24" @default.
• W2015477737 creator A5046311607 @default.
• W2015477737 creator A5051652828 @default.
• W2015477737 creator A5061681421 @default.
• W2015477737 creator A5081588665 @default.
• W2015477737 creator A5086238725 @default.
• W2015477737 date "2006-11-01" @default.
• W2015477737 modified "2023-10-14" @default.
• W2015477737 title "The clinical and cost-effectiveness of oxaliplatin and capecitabine for the adjuvant treatment of colon cancer: systematic review and economic evaluation" @default.
• W2015477737 doi "https://doi.org/10.3310/hta10410" @default.
• W2015477737 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17049138" @default.
• W2015477737 hasPublicationYear "2006" @default.
• W2015477737 type Work @default.
• W2015477737 sameAs 2015477737 @default.
• W2015477737 citedByCount "33" @default.
• W2015477737 countsByYear W20154777372012 @default.
• W2015477737 countsByYear W20154777372013 @default.
• W2015477737 countsByYear W20154777372014 @default.
• W2015477737 countsByYear W20154777372015 @default.
• W2015477737 countsByYear W20154777372016 @default.
• W2015477737 countsByYear W20154777372017 @default.
• W2015477737 countsByYear W20154777372018 @default.
• W2015477737 countsByYear W20154777372022 @default.
• W2015477737 countsByYear W20154777372023 @default.
• W2015477737 crossrefType "journal-article" @default.
• W2015477737 hasAuthorship W2015477737A5046311607 @default.
• W2015477737 hasAuthorship W2015477737A5051652828 @default.
• W2015477737 hasAuthorship W2015477737A5061681421 @default.
• W2015477737 hasAuthorship W2015477737A5081588665 @default.
• W2015477737 hasAuthorship W2015477737A5086238725 @default.
• W2015477737 hasBestOaLocation W20154777371 @default.
• W2015477737 hasConcept C112930515 @default.
• W2015477737 hasConcept C121608353 @default.
• W2015477737 hasConcept C126322002 @default.
• W2015477737 hasConcept C143998085 @default.
• W2015477737 hasConcept C197934379 @default.
• W2015477737 hasConcept C2777909004 @default.
• W2015477737 hasConcept C2780962732 @default.
• W2015477737 hasConcept C2781413609 @default.
• W2015477737 hasConcept C3019080777 @default.
• W2015477737 hasConcept C526805850 @default.
• W2015477737 hasConcept C535046627 @default.
• W2015477737 hasConcept C71924100 @default.
• W2015477737 hasConceptScore W2015477737C112930515 @default.
• W2015477737 hasConceptScore W2015477737C121608353 @default.
• W2015477737 hasConceptScore W2015477737C126322002 @default.
• W2015477737 hasConceptScore W2015477737C143998085 @default.
• W2015477737 hasConceptScore W2015477737C197934379 @default.
• W2015477737 hasConceptScore W2015477737C2777909004 @default.
• W2015477737 hasConceptScore W2015477737C2780962732 @default.
• W2015477737 hasConceptScore W2015477737C2781413609 @default.
• W2015477737 hasConceptScore W2015477737C3019080777 @default.
• W2015477737 hasConceptScore W2015477737C526805850 @default.
• W2015477737 hasConceptScore W2015477737C535046627 @default.
• W2015477737 hasConceptScore W2015477737C71924100 @default.
• W2015477737 hasFunder F4320334661 @default.
• W2015477737 hasIssue "41" @default.
• W2015477737 hasLocation W20154777371 @default.
• W2015477737 hasLocation W20154777372 @default.
• W2015477737 hasLocation W20154777373 @default.
• W2015477737 hasLocation W20154777374 @default.
• W2015477737 hasLocation W20154777375 @default.
• W2015477737 hasOpenAccess W2015477737 @default.
• W2015477737 hasPrimaryLocation W20154777371 @default.
• W2015477737 hasRelatedWork W1974190027 @default.
• W2015477737 hasRelatedWork W2029040122 @default.
• W2015477737 hasRelatedWork W2058385450 @default.
• W2015477737 hasRelatedWork W2145753255 @default.
• W2015477737 hasRelatedWork W2340032560 @default.
• W2015477737 hasRelatedWork W2374078736 @default.
• W2015477737 hasRelatedWork W2380684846 @default.
• W2015477737 hasRelatedWork W2790026560 @default.
• W2015477737 hasRelatedWork W2810309478 @default.
• W2015477737 hasRelatedWork W349909140 @default.
• W2015477737 hasVolume "10" @default.
• W2015477737 isParatext "false" @default.
• W2015477737 isRetracted "false" @default.
• W2015477737 magId "2015477737" @default.
• W2015477737 workType "article" @default.